The cellular phenotype of Roberts syndrome fibroblasts as revealed by ectopic expression of ESCO2 - PubMed
- ️Thu Jan 01 2009
doi: 10.1371/journal.pone.0006936.
Barbara C Godthelp, Wouter van Zon, Djoke van Gosliga, Anneke B Oostra, Jûrgen Steltenpool, Jan de Groot, Rik J Scheper, Rob M Wolthuis, Quinten Waisfisz, Firouz Darroudi, Hans Joenje, Johan P de Winter
Affiliations
- PMID: 19738907
- PMCID: PMC2734174
- DOI: 10.1371/journal.pone.0006936
The cellular phenotype of Roberts syndrome fibroblasts as revealed by ectopic expression of ESCO2
Petra van der Lelij et al. PLoS One. 2009.
Abstract
Cohesion between sister chromatids is essential for faithful chromosome segregation. In budding yeast, the acetyltransferase Eco1/Ctf7 establishes cohesion during DNA replication in S phase and in response to DNA double strand breaks in G2/M phase. In humans two Eco1 orthologs exist: ESCO1 and ESCO2. Both proteins are required for proper sister chromatid cohesion, but their exact function is unclear at present. Since ESCO2 has been identified as the gene defective in the rare autosomal recessive cohesinopathy Roberts syndrome (RBS), cells from RBS patients can be used to elucidate the role of ESCO2. We investigated for the first time RBS cells in comparison to isogenic controls that stably express V5- or GFP-tagged ESCO2. We show that the sister chromatid cohesion defect in the transfected cell lines is rescued and suggest that ESCO2 is regulated by proteasomal degradation in a cell cycle-dependent manner. In comparison to the corrected cells RBS cells were hypersensitive to the DNA-damaging agents mitomycin C, camptothecin and etoposide, while no particular sensitivity to UV, ionizing radiation, hydroxyurea or aphidicolin was found. The cohesion defect of RBS cells and their hypersensitivity to DNA-damaging agents were not corrected by a patient-derived ESCO2 acetyltransferase mutant (W539G), indicating that the acetyltransferase activity of ESCO2 is essential for its function. In contrast to a previous study on cells from patients with Cornelia de Lange syndrome, another cohesinopathy, RBS cells failed to exhibit excessive chromosome aberrations after irradiation in G2 phase of the cell cycle. Our results point at an S phase-specific role for ESCO2 in the maintenance of genome stability.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
![Figure 1](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec41/2734174/d761841fb1f3/pone.0006936.g001.gif)
Stable VU1199-F SV40 cell lines expressing V5- or GFP-tagged ESCO2 were obtained by transfection and neomycin selection. (A) Whole cell extracts were analyzed for ESCO2 or GFP expression by Western blotting with an ESCO2- or GFP-specific antibody. Tubulin served as a loading control. The VU1199-F SV40 cell line stably transfected with a GFP construct served as a control for cells expressing GFP protein only. (B) Nuclear localization of V5-ESCO2, GFP-ESCO2 and GFP-ESCO2 (W539G) in the stably transfected VU1199-F SV40 fibroblasts. Cells were fixed with 4% methanol-free formaldehyde solution and the V5-ESCO2 expressing cell line was probed with an anti-V5 antibody. Nuclei were stained with ToPro3. (C) Railroad chromosomes in RBS immortal fibroblasts and complemented cell lines. Fifty metaphases per cell line were scored for the presence of railroad chromosomes, from coded slides; the percentage of metaphases containing one or more railroad chromosome was calculated.
![Figure 2](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec41/2734174/7ba334452cbb/pone.0006936.g002.gif)
VU1199-F SV40 cells stably expressing V5-ESCO2 were synchronized by a double aphidicolin block and mitotic shake-off and samples were analyzed for (A) ESCO2 expression on Western blot and (B) DNA content by flow cytometry. (C) Cell cycle distribution related to GFP-ESCO2 expression was measured by flow cytometry in VU1199-F SV40 cells stably expressing wild type or mutant GFP-ESCO2. Cells were fixed in 70% ethanol and DNA was stained with ToPro3. Asterisk indicates a protein detected by the ESCO2 antibody which is supposed to represent a degradation product of ESCO2.
![Figure 3](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec41/2734174/6fd786eeea5e/pone.0006936.g003.gif)
(A) Fluoresence microscopy showing stabilization of ESCO2 protein by proteasome inhibitors in VU1199-F SV40 cells stably expressing wild type or mutant ESCO2. Cells were treated for 6 h with 50 µM MG-132 or 100 nM bortezomib and fixed with 100% cold methanol. Nuclei were stained with DAPI. (B) Ectopic ESCO2 is stabilized by proteasome inhibitors as shown by Western blotting. Cell lines were exposed to proteasome inhibitors for 6 h with 50 µM MG-132 or 100 nM bortezomib and analyzed for ESCO2 expression by Western blotting. Tubulin was used as loading control. (C) Endogenous ESCO2 levels in synchronized U2OS cells. Cells were arrested in G1/S phase by a thymidine block and released for 9 h to obtain cells in G2 phase. Mitotic cells were harvested by treatment with nocodazole followed by mitotic shake-off. These cells were released for 90 min to obtain early G1 phase cells. Cell lysates were analyzed for ESCO2, securin, cyclin B1 and APC expression by Western blotting. Asterisk indicates an aspecific band considered as loading control. (D) Proteasome inhibitor MG-132 stabilizes ESCO2 levels in M phase cells. U2OS cells were cultured for 4 h in the presence of 5 µM MG-132 before M phase cells were isolated. APC3 phosphorylation is shown as a control for mitotic cells. Asterisk indicates an aspecific band as loading control. (E) ESCO2 levels in unsynchronized wild type fibroblasts treated with proteasome inhibitors. LN9SV was treated for 6 h with 50 µM MG-132 or 1 µM bortezomib.
![Figure 4](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec41/2734174/1ed0fc89ccf2/pone.0006936.g004.gif)
Data are averages of at least 2 or 3 independent experiments; error bars represent standard error of the mean. VU1199-F SV40 cell line, V5-ESCO2-transfected VU1199-F SV40, GFP-ESCO2-transfected VU1199-F SV40, GFP-ESCO2 mutant (W539G)-transfected VU1199-F SV40 and wild type fibroblasts LN9SV (figures A to E) or VH10 SV40 (figures F and G) were grown for 10–12 days after treatment with X-rays or UV-C irradiation, or after continuous exposure to the indicated DNA-damaging agents. (A) Clonogenic survival after continuous MMC exposure. SV40-immortalized fibroblasts of a Fanconi anemia patient (EUFA1341, FA-N) are shown as a hypersensitive control (open circles). Clonogenic survival after continuous exposure to (B) camptothecin, (C) etoposide, (D) aphidicolin, (E) hydroxyurea. Clonogenic survival after (F) X-ray or (G) UV-C exposure.
![Figure 5](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec41/2734174/5279bd887d65/pone.0006936.g005.gif)
(A) Rad51 foci in normal and RBS cells, as determined 6 and 24 h after treatment with X-ray (12Gy) or MMC treatment (7 µM for 1 h). The percentages of cells containing more than five nuclear foci were determined. Data are the means of at least three experiments; error bars represent the standard error of the mean. (B) SCE induction in RBS cells after MMC treatment. Wild type (LN9SV), RBS (VU1199-F SV40) and RBS cells expressing V5-ESCO2, GFP-ESCO2 or GFP-ESCO2 (W539G) were either mock-treated or treated by continuous exposure to 50 nM MMC. Numbers of SCEs were counted and normalized against the number of chromosomes scored.
![Figure 6](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec41/2734174/9fd211e7530c/pone.0006936.g006.gif)
VU1199-F SV40 fibroblasts, VU1199-F corrected with V5-ESCO2 and wild type fibroblasts LN9SV were left untreated or exposed to MMC, camptothecin (CPT) or hydroxyurea (HU) for 24 h and whole cell extracts were obtained to investigate the phosphorylation of Chk-1. Vinculin and Chk-1 served as loading controls.
Similar articles
-
Gordillo M, Vega H, Trainer AH, Hou F, Sakai N, Luque R, Kayserili H, Basaran S, Skovby F, Hennekam RC, Uzielli ML, Schnur RE, Manouvrier S, Chang S, Blair E, Hurst JA, Forzano F, Meins M, Simola KO, Raas-Rothschild A, Schultz RA, McDaniel LD, Ozono K, Inui K, Zou H, Jabs EW. Gordillo M, et al. Hum Mol Genet. 2008 Jul 15;17(14):2172-80. doi: 10.1093/hmg/ddn116. Epub 2008 Apr 14. Hum Mol Genet. 2008. PMID: 18411254
-
Faramarz A, Balk JA, van Schie JJM, Oostra AB, Ghandour CA, Rooimans MA, Wolthuis RMF, de Lange J. Faramarz A, et al. PLoS One. 2020 Jan 14;15(1):e0220348. doi: 10.1371/journal.pone.0220348. eCollection 2020. PLoS One. 2020. PMID: 31935221 Free PMC article.
-
Esco1 and Esco2 regulate distinct cohesin functions during cell cycle progression.
Alomer RM, da Silva EML, Chen J, Piekarz KM, McDonald K, Sansam CG, Sansam CL, Rankin S. Alomer RM, et al. Proc Natl Acad Sci U S A. 2017 Sep 12;114(37):9906-9911. doi: 10.1073/pnas.1708291114. Epub 2017 Aug 28. Proc Natl Acad Sci U S A. 2017. PMID: 28847955 Free PMC article.
-
The non-redundant function of cohesin acetyltransferase Esco2: some answers and new questions.
Whelan G, Kreidl E, Peters JM, Eichele G. Whelan G, et al. Nucleus. 2012 Jul 1;3(4):330-4. doi: 10.4161/nucl.20440. Epub 2012 May 22. Nucleus. 2012. PMID: 22614755 Review.
-
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Piché J, Van Vliet PP, Pucéat M, Andelfinger G. Piché J, et al. Cell Cycle. 2019 Nov;18(21):2828-2848. doi: 10.1080/15384101.2019.1658476. Epub 2019 Sep 13. Cell Cycle. 2019. PMID: 31516082 Free PMC article. Review.
Cited by
-
Bolaños-Villegas P, Yang X, Wang HJ, Juan CT, Chuang MH, Makaroff CA, Jauh GY. Bolaños-Villegas P, et al. Plant J. 2013 Sep;75(6):927-40. doi: 10.1111/tpj.12261. Epub 2013 Jul 20. Plant J. 2013. PMID: 23750584 Free PMC article.
-
Cohesinopathies, gene expression, and chromatin organization.
Bose T, Gerton JL. Bose T, et al. J Cell Biol. 2010 Apr 19;189(2):201-10. doi: 10.1083/jcb.200912129. J Cell Biol. 2010. PMID: 20404106 Free PMC article. Review.
-
Cohesinopathies of a feather flock together.
Skibbens RV, Colquhoun JM, Green MJ, Molnar CA, Sin DN, Sullivan BJ, Tanzosh EE. Skibbens RV, et al. PLoS Genet. 2013;9(12):e1004036. doi: 10.1371/journal.pgen.1004036. Epub 2013 Dec 19. PLoS Genet. 2013. PMID: 24367282 Free PMC article. Review.
-
The ancient and evolving roles of cohesin in gene expression and DNA repair.
Dorsett D, Ström L. Dorsett D, et al. Curr Biol. 2012 Apr 10;22(7):R240-50. doi: 10.1016/j.cub.2012.02.046. Curr Biol. 2012. PMID: 22497943 Free PMC article. Review.
-
The cohesin modifier ESCO2 is stable during DNA replication.
Jevitt AM, Rankin BD, Chen J, Rankin S. Jevitt AM, et al. Chromosome Res. 2023 Jan 28;31(1):6. doi: 10.1007/s10577-023-09711-1. Chromosome Res. 2023. PMID: 36708487 Free PMC article.
References
-
- Van Den Berg DJ, Francke U. Roberts syndrome: a review of 100 cases and a new rating system for severity. Am J Med Genet. 1993;47:1104–1123. - PubMed
-
- Vega H, Waisfisz Q, Gordillo M, Sakai N, Yanagihara I, et al. Roberts syndrome is caused by mutations in ESCO2, a human homolog of yeast ECO1 that is essential for the establishment of sister chromatid cohesion. Nat Genet. 2005;37:468–470. - PubMed
-
- Sjogren C, Nasmyth K. Sister chromatid cohesion is required for postreplicative double-strand break repair in Saccharomyces cerevisiae. Curr Biol. 2001;11:991–995. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials